OTC cough medicines may have some temporary benefit, but they don't penetrate the nerves in the airways, which are believed to be the mechanism behind refractory chronic cough, says Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust.
Although they may have some benefit, OTC cough medicines don't penetrate the nerves in the airways, which are believed to be the mechanism behind refractory chronic cough, says Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust.
Transcript
How do novel therapies being evaluated in clinical trials better address cough compared with over-the-counter therapies—for instance, are they getting at the underlying mechanisms?
I suspect they are. It's a little tricky to say because many of the over-the-counter cough medicines have been around for a long time. And that means they were evaluated many years ago, when the trials that we did and the evidence base for licensing therapies was quite different. Also, most of the over-the-counter cough medicines are very much aimed at treating acute cough, so coughing associated with viral upper respiratory tract infections, coughs and colds, which do get better by themselves anyway. Whereas the newer therapies are much more aimed at treating patients with refractory chronic coughing, so cough that's been there for more than 8 weeks, which is much longer than you'd expect just from a postviral cough. And I do think that whilst many of the over-the-counter medicines may well help soothe the throat, improve the cough tickling, perhaps suppress the cough to some degree if it contains things like codeine or dextromethorphan, it's probably not tapping into precise mechanisms in the same way that some of the new treatments are, which, certainly with the P2X3 antagonists, we believe most of the drugs been tested don't penetrate the central nervous system much and are actually addressing things that are activating the nerves in the airways like ATP, which is quite a specific mechanism.
What Mass General Brigham is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Posters Highlight Racial Gaps in PSA Screening, Prostate Cancer Risk
May 4th 2024Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future prostate cancer risk.
Read More